Diagnosed with Cancer? Your two greatest challenges are understanding cancer and understanding possible side effects from chemo and radiation. Knowledge is Power!
Learn about conventional, complementary, and integrative therapies.
Dealing with treatment side effects? Learn about evidence-based therapies to alleviate your symptoms.
Click the orange button to the right to learn more.
- You are here:
- Home »
- Blog »
- Lung Cancer »
- Fenbendazole and Lung Cancer
Fenbendazole and Lung Cancer
Fenbendazole and Lung Cancer: Separating Hype from Evidence. Fenbendazole (fenben) has generated buzz online as a potential anti-cancer agent for a range of tumors — lung cancer included. Anecdotes on social media often describe dramatic “miracle cures.” But what does real science show for lung cancer specifically?
I am a long-term survivor of an incurable blood cancer called multiple myeloma. I have gone to great lengths and taken great risks in an effort to manage my blood cancer. I can understand why cancer patients hear about non-conventional therapies and want to understand more about them as possible therapies.
The post below is PeopleBeatingCancer’s effort to weigh in on the fenben and lung cancer debate. Please scroll down the page, post a question or a comment if you have any questions.
Thank you,
David Emerson
- Cancer Survivor
- Cancer Coach
- Director PeopleBeatingCancer
How Fenbendazole Could Treat Cancer (and Why It Won’t)
What Is Fenbendazole?
Fenbendazole is a veterinary antiparasitic drug commonly used to treat worms in animals. Because it affects microtubule dynamics — structures vital to cell division — some researchers have speculated that it might also impede cancer cell growth. However:
- Fenbendazole is not approved for human use
- It has no FDA-approved indication for lung cancer
- It lacks human dosing standards or quality controls
Moreover, self-reported use in humans has occasionally led to serious liver damage.
Why the Interest in Lung Cancer?
Lung cancer remains a leading cause of cancer-related death worldwide, and despite advances in surgery, chemotherapy, radiotherapy, and targeted therapies, prognosis can still be poor in advanced stages. Interest in repurposed drugs like fenbendazole reflects the need for more effective treatments.
In laboratory settings, researchers have explored combinations of fenbendazole with other compounds. For example:
-
A 2024 laboratory study found that fenbendazole combined with diisopropylamine dichloroacetate (DADA) inhibited the growth of A549 lung cancer cells and induced apoptosis — cell death — in vitro.
https://pubmed.ncbi.nlm.nih.gov/39477286/
These findings suggest possible mechanistic effects in cell culture, but they do not provide evidence of benefit in patients.
What About Human Evidence?
At present:
- There are no robust human clinical trials demonstrating that fenbendazole is safe or effective for lung cancer.
- Most reports of benefit are anecdotal and not supported by controlled research. In one widely circulated story, a person claiming a cure was actually enrolled in a clinical immunotherapy study at the same time — making it impossible to know what caused the response.
Case reports of off-label use have also highlighted significant safety concerns, including liver injury that resolved when the drug was stopped.
Potential Risks and Unknowns
Because fenbendazole was developed for animals:
- Human dosing and metabolism are unclear
- Purity and formulation vary in veterinary products
- Possible interactions with standard lung cancer treatments are unknown
- There are no guidelines supporting its use in oncology
Some clinicians worry that off-label use could potentially accelerate tumor growth in early disease — a theoretical concern in cancer research.
Why Lab Results Aren’t Enough
Preclinical studies in cells and animals help scientists understand biological possibilities, but:
- Human cancers are far more complex than cell lines.
- Drug absorption and metabolism in humans differ substantially.
- Many agents fail in clinical trials despite promising lab data.
Until controlled clinical research is done, fenbendazole’s anticancer effects remain speculative.
Bottom Line for Lung Cancer Patients
Here’s the balanced conclusion:
- ✔ Fenbendazole has shown some anticancer activity in laboratory models.
- ✖ There is no reliable clinical evidence that it treats lung cancer in humans.
- ✖ It is not FDA-approved for any cancer treatment.
- ✖ Safety, dosing, and interactions with standard therapies are unknown.
Fenbendazole should not be considered an evidence-based therapy for lung cancer.
If You’re Considering Fenbendazole
Before considering any off-label use:
- Talk openly with your oncologist or cancer care team.
- Consider evidence-based treatments with known safety and effectiveness.
- Avoid delaying or substituting proven therapies based on unverified claims.
Cancer care decisions should always be based on robust evidence, patient safety, and expert guidance — not anecdote.
- Citations
-
Fenbendazole
American Cancer Society
What to Know About FenbendazoleOct 21, 2025 — People have self-reported becoming “cancer-free” after taking fenbendazole for breast, prostate, skin, and other cancers. But in most cases …Read more -
PubMed
Fenbendazole and Diisopropylamine Dichloroacetate … -
CancerChoices
Fenbendazole and Cancer: Use and RisksJan 28, 2025 — The potential for fenbendazole to lead to faster growth of cancers is particularly concerning for individuals with earl
Fenbendazole and Lung Cancer Fenbendazole and Lung Cancer Fenbendazole and Lung Cancer